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Introduction
EphA2, a member of Eph family receptor tyrosine kinases, is 
frequently overexpressed in a variety of human cancers, includ-
ing breast cancers (Merlos-Suárez and Batlle, 2008; Pasquale, 
2008). Overexpression of EphA2 is associated with an aggres-
sive and metastatic cellular phenotype in breast cancers, and re-
cent studies have revealed that EphA2 acts as a downstream 
effector of EGF receptors to promote cancer cell motility and in-
vasion, independently of the ligand ephrin stimulation (Zelinski 
et al., 2001; Macrae et al., 2005; Larsen et al., 2007; Brantley-
Sieders et al., 2008; Miao et al., 2009). Conversely, stimulation 
of EphA2 with its ligand ephrinA1 in cancer cells inhibits cell 
proliferation and migration (Miao et al., 2009). However, the 
mechanisms underlying the oncogenic effects of EphA2 remain 
poorly understood.
Rho family small GTPases play pivotal roles in the regu-
lation of the actin cytoskeleton and cell migration and also 
contribute to many steps in cancer initiation and progression 
(Etienne-Manneville and Hall, 2002; Sahai and Marshall, 2002; 
Vega and Ridley, 2008). Among Rho GTPases, Rac is activated 
at the leading edge of motile cells and induces the formation   
of actin-rich lamellipodia protrusions, which serves as a major 
driving force of cell movement (Etienne-Manneville and Hall, 
2002). Rac also plays a key role in the cancer cell movement 
and formation of protrusions in invading cancer cells (Kurisu   
et al., 2005; Sanz-Moreno et al., 2008; Yamazaki et al., 2009). 
The major downstream proteins for Rac that mediate actin poly-
merization in lamellipodia protrusions are the WAVE family 
proteins, the activators of the Arp2/3 complex (Miki et al., 1998; 
Kurisu et al., 2005; Sanz-Moreno et al., 2008). Activated Arp2/3 
complex induces rapid polymerization of actin and the forma-
tion of the branched actin filaments present in lamellipodia 
(Pollard and Borisy, 2003).
Activation of Rho family GTPases requires GDP–GTP ex-
change catalyzed by various guanine nucleotide exchange fac-
tors (GEFs). The major class of GEFs is the Dbl family GEFs 
that contain the Dbl homology (DH)–pleckstrin homology (PH; 
DH-PH) tandem domain and mediate the GDP–GTP exchange 
through the DH domain. The second class of GEFs for Rho fam-
ily GTPases is the Dock family GEFs that have no DH-PH tan-
dem domain. Instead, they contain a new conserved domain that 
directly interacts with Rho GTPase and mediates its GDP–GTP 
exchange (Brugnera et al., 2002; Côté and Vuori, 2002; Meller   
et al., 2002). Presently, 11 mammalian Dock family members 
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Figure 1.  Ephexin4 activates RhoG. (A) Flag-tagged Ephexin4 expressed in HEK293T cells was used in pull-down assays with nucleotide-free forms of 
GST-fused Rho family GTPases. Bound proteins were analyzed by immunoblotting with anti-Flag antibody. (B) GST-fused DH-PH domain of Ephexin4 puri-
fied from E. coli was incubated with purified RhoG or Rac1, and nucleotide exchange activity was measured in vitro using a mant-GTP fluorescence-based 
assay. The change in the rate of mant-GTP incorporation into GST-RhoG or -Rac1 was monitored. Nucleotide exchange on GST-Rac1 was stimulated by 
purified Dock4 that was used as a positive control (not depicted). (C) Cell lysates from HEK293T cells cotransfected with Flag-Ephexin4 and Myc-RhoG 
were incubated with GST-ELMO, and bound Myc-RhoG was detected with anti-Myc antibody. Relative Myc-RhoG activity was determined by the amount 
of GTP-bound Myc-RhoG bound to GST-ELMO normalized to the amount of Myc-RhoG in cell lysates analyzed by ImageJ software. Data are presented 
as the means ± SEM from three independent experiments (*, P < 0.05; t test). (D) The Rac1 activity in HEK293T cells transfected with Flag-Ephexin4 or 
Flag-Dock180 was analyzed by the GST-CRIB pull-down assay. (E) The Cdc42 activity in HEK293T cells transfected with Flag-Ephexin4 or Flag-Zizimin1 463 Role of Ephexin4 in EphA2 signaling • Hiramoto-Yamaki et al.
through the activation of RhoG in breast cancer cells. In addi-
tion, the ELMO2–Dock4 complex is involved in the downstream 
signaling pathway of RhoG. Our findings provide a novel signal 
transduction pathway that contributes to increased migration and 
invasion of breast cancers and thus may provide information 
useful for developing new therapeutic strategies that delay or 
prevent the process of breast cancer cell invasion.
Results
The DH domain of Ephexin4 shares high amino acid sequence 
homology with that of SGEF (60%), which is known as a RhoG 
GEF (Ellerbroek et al., 2004). Therefore, we first examined the 
interaction of Ephexin4 with RhoG and other well-characterized 
Rho family GTPases by pull-down assays with GST-fused Rho 
GTPases. Flag-tagged Ephexin4 expressed in HEK293T cells 
bound to the nucleotide-free forms of RhoG and Rac1 but not to 
those of RhoA and Cdc42 (Fig. 1 A). To identify RhoG, Rac1, or 
both as a substrate for Ephexin4, purified GST-fused DH-PH   
domain of Ephexin4 was incubated with purified RhoG or Rac1 
in vitro, and nucleotide exchange activity was measured using   
an N-methylanthraniloyl (mant)-GTP fluorescence-based assay.   
Although the DH-PH domain of Ephexin4 did not exchange   
nucleotide on Rac1, it possessed GEF activity of RhoG in vitro 
(Fig. 1 B). We next examined whether Ephexin4 activates RhoG 
in cells by using the ability of purified GST-fused N-terminal 
RhoG-binding  region  of  ELMO  to  specifically  interact  with 
GTP-bound active RhoG (Katoh and Negishi, 2003). Expression 
of Ephexin4 in HEK293T cells increased the amount of active 
exogenously expressed Myc-tagged RhoG about sixfold over 
the basal level (Fig. 1 C). However, we could observe no obvious 
increase in the activities of Rac1 and Cdc42 in HEK293T cells 
by expression of Ephexin4 in pull-down assays with GST-fused 
Cdc42/Rac1 interactive binding (CRIB) domain of Pak to 
precipitate GTP-bound active Rac1 or Cdc42 (Fig. 1, D and E; 
Dock180 and Zizimin1 were used as positive controls for activa-
tion of Rac1 and Cdc42, respectively). Other Ephexin subfamily 
members activate RhoA (Shamah et al., 2001; Ogita et al., 2003; 
Wang et al., 2004; Xie et al., 2005), but we could not detect the 
increase in RhoA activity in cells expressing Ephexin4, as mea-
sured by pull-down assays with GST-fused Rho-binding domain 
(RBD) of Rhotekin (Fig. 1 F; Ephexin1 was used as a positive 
control for RhoA activation). To confirm the activation of RhoG 
by Ephexin4, we used HeLa cells, which express a high amount 
of endogenous RhoG, and expression of Flag-Ephexin4 in HeLa 
cells enhanced endogenous RhoG activity (Fig. 1 G). In addi-
tion, HeLa cells expressing Flag-Ephexin4 or Myc-tagged con-
stitutively  active  RhoG  (Myc–RhoG-V12)  showed  extensive 
membrane ruffling at dorsal surfaces (80% of the transfected 
cells), which is a typical morphology of RhoG activation (Fig. 1 H; 
have been identified and are classified into four subfamilies, the 
Dock180 subfamily (Dock180, Dock2, and Dock5), Dock4 sub-
family (Dock3/MOCA and Dock4), Dock9 subfamily (Dock9/
Zizimin1, Dock10/Zizimin3, and Dock11/Zizimin2), and Dock7 
subfamily (Dock6, Dock7, and Dock8; Côté and Vuori, 2002; 
Meller et al., 2005). They activate specific members of Rho 
GTPases; the Dock180 and Dock4 subfamilies specifically activate 
Rac, whereas the Zizimin subfamily activates Cdc42 (Kiyokawa 
et al., 1998; Nishihara et al., 1999; Meller et al., 2002; Namekata 
et al., 2004; Hiramoto et al., 2006). In contrast, Dock7 subfamily 
members activate both Rac and Cdc42 (Miyamoto et al., 2007; 
Yamauchi et al., 2008). Dock family members play key roles in 
a variety of important cellular functions, including cell migra-
tion,  phagocytosis,  and  neuronal  axon  and  dendrite  morpho-
genesis (Meller et al., 2005; Côté and Vuori, 2007; Miyamoto and 
Yamauchi, 2010). In addition, several recent studies have identi-
fied their roles in cancer cell migration and invasion. Dock180 
promotes glioma cell invasion, whereas Dock3 and Dock10 me-
diate different modes of cell movement and invasion in mela-
noma cells (Jarzynka et al., 2007; Gadea et al., 2008; Sanz-Moreno 
et al., 2008).
The small GTPase RhoG is a key upstream regulator of 
Rac in migrating cells (Katoh and Negishi, 2003; Hiramoto   
et al., 2006; Katoh et al., 2006; Elfenbein et al., 2009). RhoG 
activates Rac through its effector ELMO (Katoh and Negishi, 
2003). ELMO forms a complex with Dock180 or Dock4, and they 
serve as a functional GEF for Rac in intact cells (Gumienny   
et al., 2001; Brugnera et al., 2002; Hiramoto et al., 2006). The 
interaction of RhoG with ELMO induces translocation of the 
ELMO–Dock180  or  ELMO–Dock4  complex  from  the  cyto-
plasm to the plasma membrane and activates Rac1 to promote 
lamellipodium formation and cell migration (Katoh and Negishi, 
2003; Hiramoto et al., 2006; Katoh et al., 2006). However, the 
upstream regulators of RhoG activity in the regulation of cell 
migration still remain obscure.
Ephexin is a subfamily of Dbl family GEFs that interacts 
directly with EphA receptors (Shamah et al., 2001; Sahin   
et al., 2005). At least five members of the Ephexin subfamily 
(Ephexin1–5) have been reported, and Ephexin1 (ARHGEF27/
NGEF), Ephexin2 (ARHGEF19/WGEF), Ephexin3 (ARHGEF5/
TIM1),  and  Ephexin5  (ARHGEF15/Vsm–Rho  GEF)  activate 
RhoA (Shamah et al., 2001; Ogita et al., 2003; Wang et al., 2004; 
Xie et al., 2005). The function of Ephexin1 is well characterized, 
and it has been reported that Ephexin1 regulates axon guidance 
and spine morphogenesis through the interaction with EphA4 
(Sahin et al., 2005; Fu et al., 2007). In contrast, the functions and 
biochemical properties of Ephexin4 (ARHGEF16/neuroblastoma) 
still remain unknown. In this study, we identified Ephexin4 as a 
GEF for RhoG. Ephexin4 interacts with EphA2 and mediates   
ligand-independent  promotion  of  cell  migration  and  invasion 
was analyzed by the GST-CRIB pull-down assay. (F) The RhoA activity in HEK293T cells transfected with Flag-Ephexin4 or Flag-Ephexin1 was analyzed 
by the GST–Rhotekin-RBD pull-down assay. (G) HeLa cells were transfected with Flag-Ephexin4, and endogenous RhoG activity was analyzed by the GST-
ELMO pull-down assay. (H) Ephexin4 induces dorsal ruffling in HeLa cells. HeLa cells transfected with Flag-Ephexin4 or Myc–RhoG-V12 were subjected to   
immunofluorescent staining for Ephexin4 (anti-Flag), RhoG-V12 (anti-Myc), and F-actin (phalloidin). Images were captured at the basal and dorsal surfaces 
of the cells. Cells with dorsal ruffling were quantified, and results were expressed as a percentage of the number of the transfected cells. Data are presented 
as the means ± SEM from three independent experiments in which at least 100 cells were counted. Bars, 20 µm.
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We raised an antibody against Ephexin4 and found that 
Ephexin4 was expressed in highly invasive MDA-MB-231 breast 
cancer cells (Fig. 2 A). It has been well noticed that EphA2 is 
Blangy  et  al.,  2000).  However,  many  untransfected  parental 
HeLa cells formed stress fibers but did not form dorsal ruffling. 
These results indicate that Ephexin4 activates RhoG in cells.
Figure 2.  Ephexin4 interacts with EphA2. (A) Cell lysates from MDA-MB-231 cells were immunoprecipitated with control or anti-EphA2 antibody, and 
bound proteins and total cell lysates were analyzed by immunoblotting with anti-EphA2 and anti-Ephexin4 antibodies. (B) HEK293T cells were transfected 
with Myc-EphA2 alone or together with Flag-Ephexin4, and the cell lysates were immunoprecipitated with anti-Flag antibody. Bound proteins and total 
cell lysates were analyzed by immunoblotting with anti-Flag and anti-EphA2 antibodies. (C and D) HEK293T cells were cotransfected with Flag-Ephexin4 
(WT and DH) and Myc-EphA2 (WT, KD, and SAM) as indicated. The cell lysates were immunoprecipitated with ephrinA1-Fc, and bound proteins and 
total cell lysates were analyzed by immunoblotting with anti-Flag and anti-Myc antibodies. Numbers indicate amino acid position within the sequence. 
Relative immunoprecipitated Ephexin4 was determined by the amount of immunoprecipitated Flag-Ephexin4 bound to Myc-EphA2 normalized to the 
amount of Flag-Ephexin4 in cell lysates analyzed by ImageJ software. Data are presented as the means ± SEM from four independent experiments. KD, 
kinase domain; SH3, Src-homology 3; TM, transmembrane. (E) Flag–EphA2-KD expressed in HEK293T cells was used in pull-down assays with GST-fused 
Ephexin4-DH. Bound proteins were analyzed by immunoblotting with anti-Flag antibody. (F) Cell lysates from HEK293T cells cotransfected with Myc-RhoG 
and Flag–Ephexin4-WT or Ephexin4-DH were incubated with GST-ELMO, and bound Myc-RhoG was detected with anti-Myc antibody. Relative Myc-RhoG 
activity was determined by the amount of GTP-bound Myc-RhoG bound to GST-ELMO normalized to the amount of Myc-RhoG in cell lysates analyzed by 
ImageJ software. Data are presented as the means ± SEM from four independent experiments (*, P < 0.05; t test). IP, immunoprecipitation.465 Role of Ephexin4 in EphA2 signaling • Hiramoto-Yamaki et al.
the effect of Ephexin4 or RhoG knockdown on the migration of 
MDA-MB-231 cells toward EGF-containing medium and found 
that knockdown of Ephexin4 by shEphexin4-1 or shEphexin4-2, 
targeting different regions of human Ephexin4 mRNA, or knock-
down of RhoG by RhoG-specific shRNA (shRhoG; Katoh et al., 
2006) also significantly blocked the migration (Fig. 3 C). Expres-
sion of control Luciferase shRNA (shControl) had no effect on 
the migration of MDA-MB-231 cells compared with untrans-
fected cells (unpublished data). Because the shEphexin4-1   
targets Ephexin4 mRNA 3 untranslated region, we could per-
form rescue experiments by cotransfection with the plasmid   
expressing  Flag-tagged  Ephexin4,  which  contains  only  the   
coding region of Ephexin4. Cotransfection with Flag-Ephexin4 
(+Ephexin4-WT) or constitutively active RhoG (+RhoG-V12) 
completely rescued the defect in cell migration caused by 
shEphexin4-1  (Fig.  3  D).  However,  Flag–Ephexin4-DH, 
which did not activate RhoG (Fig. 2 F), failed to rescue the   
defect by knockdown of Ephexin4 and also suppressed migra-
tion of the control cells (Fig. 3 E), suggesting that Ephexin4   
promotes migration of MDA-MB-231 cells through activation of 
RhoG. In contrast, expression of Myc-tagged EphA2 (+EphA2), 
which could rescue the cell migration defect caused by shEphA2-2 
(shEphA2-2  targets  the  3  untranslated  region  of  EphA2 
mRNA), had little effect on cell migration in Ephexin4 or RhoG 
knockdown cells (Fig. 3, D and F). In addition, the cell migra-
tion defect caused by shEphA2-2 was rescued by expression of 
RhoG-V12 (Fig. 3 G). Collectively, these results suggest that 
Ephexin4 and RhoG act downstream of EphA2 in the promo-
tion of cell migration in MDA-MB-231 cells. Simultaneous 
knockdown  of  EphA2  and  Ephexin4  by  shEphA2-2  and 
shEphexin4-1 had no additive inhibitory effect on cell migra-
tion (Fig. 3 H). This result also supports the idea that EphA2 
and Ephexin4 act in the same pathway. Because MDA-MB-231 
cells are well known as highly invasive cells, we used Matrigel 
invasion assays to examine whether EphA2, Ephexin4, and 
RhoG also contribute to the invasion of MDA-MB-231 cells 
and found that knockdown of EphA2, Ephexin4, and RhoG 
markedly suppressed the EGF-induced Matrigel invasion in 
MDA-MB-231 cells (Fig. 3 I).
We next examined whether EphA2 and Ephexin4 regulate 
RhoG activity in MDA-MB-231 cells after stimulation with EGF 
by  the  pull-down  assay  with  GST-fused  ELMO.  Stimulation 
with EGF induced a rapid increase in the amount of GTP-bound 
RhoG within 1 min, and then the level decreased within 5 min 
(Fig. 4 A). Knockdown of Ephexin4 or EphA2 in MDA-MB-231 
cells significantly suppressed the activation of RhoG induced by 
EGF stimulation (Fig. 4, B and C). These results suggest that 
EphA2 and Ephexin4 mediate RhoG activation in response to 
EGF stimulation in MDA-MB-231 cells.
To verify the involvement of Ephexin4 in the EphA2- 
mediated promotion of cell migration, we used the noninvasive 
breast cancer cell line MCF7, which expresses a moderate level 
of endogenous EphA2 compared with that in MDA-MB-231 
(Fig. 5 A). In addition, Ephexin4 is expressed in MCF7 cells, and 
the interaction with EphA2 was also detected by immunoprecip-
itation (Fig. 5 B). Ectopic expression of Myc-tagged EphA2 in 
MCF7 cells promoted cell migration in the absence of ephrin 
highly expressed in invasive human breast cancer cell lines, in-
cluding MDA-MB-231 cells (Zelinski et al., 2001; Macrae et al., 
2005). To address the possibility that the interaction between   
endogenous  Ephexin4  and  EphA2  occurred  in  breast  cancer 
cells, we performed immunoprecipitation from MDA-MB-231 
cell lysates with anti-EphA2 antibody. Immunoblot analysis of 
the  immunoprecipitates  demonstrates  the  specific  interaction   
between Ephexin4 and EphA2 (Fig. 2 A). We also observed the   
interaction  between  Flag-tagged  Ephexin4  and  Myc-tagged 
EphA2 expressed in HEK293T cells by immunoprecipitation with 
anti-Flag antibody (Fig. 2 B). To identify the region responsible for 
the interaction between EphA2 and Ephexin4, we constructed 
deletion mutants of EphA2 and Ephexin4. The cytoplasmic region 
of Eph receptors contains a protein tyrosine kinase domain and   
a sterile  motif (SAM) domain, and the interaction between 
Ephexin1 and EphA4 is mediated through the DH-PH motif of 
Ephexin1 and the kinase domain of EphA4 (Shamah et al., 
2001). HEK293T cells were cotransfected with Flag-tagged 
Ephexin4 and Myc-tagged wild-type (WT) or deletion mutants 
of EphA2 (EphA2-KD, lacking the kinase domain; EphA2-
SAM, lacking the SAM domain), and EphA2 was immuno-
precipitated from the cell lysates with recombinant ephrinA1- 
Fc chimera. Ephexin4 was coimmunoprecipitated with WT EphA2 
(EphA2-WT). However, deletion of the kinase domain reduced 
the interaction (Fig. 2 C). In contrast, the interaction between 
Ephexin4 and EphA2 was enhanced by deletion of the SAM do-
main, suggesting a possible inhibitory role of the SAM domain 
in their interaction. Deletion of the DH domain of Ephexin4 
(Ephexin4-DH) also reduced the interaction (Fig. 2 D). The   
interaction between the kinase domain of EphA2 and the DH 
domain of Ephexin4 was confirmed by a pull-down assay with 
Flag-tagged kinase domain of EphA2 and GST-fused DH do-
main of Ephexin4 (Fig. 2 E). In contrast, the interaction between 
Ephexin4 and EphA2 was independent of the ligand ephrinA1 
stimulation (unpublished data), which is a result similar to that 
observed in the interaction between Ephexin1 and EphA4 (Sahin 
et al., 2005; Fu et al., 2007).
EphA2 is overexpressed in many cancer cell lines and 
promotes cell migration in a ligand-independent manner (Zelinski 
et al., 2001; Macrae et al., 2005; Larsen et al., 2007; Brantley-
Sieders et al., 2008; Miao et al., 2009). To investigate the roles 
of Ephexin4 and RhoG in the promotion of cancer cell migra-
tion mediated by EphA2, we performed RNAi-mediated knock-
down of Ephexin4, RhoG, and EphA2 in MDA-MB-231 cells 
using short hairpin RNA (shRNA) expression vectors, which 
effectively reduced the amounts of the endogenous proteins 
(Fig. 3 A). We evaluated the effect of knockdown of these pro-
teins on the migration of MDA-MB-231 cells in Transwell mi-
gration  assays  by  using  EGF  as  a  chemoattractant  because 
MDA-MB-231 cells show enhanced cell migration and invasion 
in response to EGF (Hynes and Lane, 2005). Knockdown of 
EphA2  by  shEphA2-1  or  shEphA2-2,  targeting  different   
sequences of human EphA2 mRNA, significantly impaired 
the ability of MDA-MB-231 cells to migrate toward EGF- 
containing medium (Fig. 3 B), suggesting that EphA2 mediates a 
ligand-independent promotion of chemotactic migration in MDA- 
MB-231 cells in response to EGF stimulation. We next investigated JCB • VOLUME 190 • NUMBER 3 • 2010   466
Figure 3.  Ephexin4 and RhoG mediate promotion of cell migration and invasion by EphA2 in MDA-MB-231 cells. (A) Cell lysates from MDA-MB-231 cells trans-
fected with the indicated shRNAs were analyzed by immunoblotting with antibodies against Ephexin4, EphA2, RhoG, and -tubulin. (B and C) Transwell migration 
assays using MDA-MB-231 transfected with YFP together with the indicated shRNAs in the presence of 10 ng/ml EGF for 4–6 h. Data are presented as the means ±   
SEM from three independent experiments (*, P < 0.05; **, P < 0.01; t test). (D–H) Transwell migration assays using MDA-MB-231 cells transfected with YFP 
and the indicated plasmids in the presence of EGF for 6 h. Data are presented as the means ± SEM from three or four independent experiments (*, P < 0.05;   
**, P < 0.01; ***, P < 0.001; ns, not significant; t test). (I) Matrigel invasion assays using MDA-MB-231 cells cotransfected with YFP and the indicated shRNAs 
in the presence of EGF for 24 h. Data are presented as the means ± SEM from three independent experiments (**, P < 0.01; ***, P < 0.001; t test).467 Role of Ephexin4 in EphA2 signaling • Hiramoto-Yamaki et al.
endogenous ELMO2-mediated interaction. However, our results 
cannot rule out the possibility that EphA2 can bind to Dock4 
without  ELMO2.  Immunoprecipitation  analysis  with  deletion 
mutants of EphA2 showed that the kinase domain of EphA2 was 
important for the interaction with ELMO2 (Fig. 6 D). Interest-
ingly, the interaction between EphA2 and ELMO2 was enhanced 
by coexpression with Myc–RhoG-V12 but not by coexpression 
with Myc–RhoG-V12A37, a mutant of RhoG-V12 which fails to 
interact with ELMO2 (Fig. 6 E; Katoh and Negishi, 2003). These 
results suggest that activated RhoG binds to ELMO2 and recruits 
ELMO2 and Dock4 to form a complex with EphA2. An immuno-
precipitation analysis with anti-EphA2 antibody shows that inter-
action of endogenous EphA2 with ELMO2–Dock4 was reduced 
by knockdown of RhoG in MDA-MB-231 cells (Fig. 6 F). This 
result also supports the conclusion that RhoG regulates the inter-
action of ELMO2 with EphA2. In contrast, HA-ELMO2 and 
Myc-EphA2 were coimmunoprecipitated with Flag-Ephexin4 in 
HEK293T cells transfected with Flag-Ephexin4, Myc-EphA2, 
and HA-ELMO2 (Fig. 6 G), suggesting that Ephexin4 was also 
present in the same complex. In our immunoprecipitation experi-
ments using Fc-fused ephrinA1, the bands of HA-ELMO2 were 
weakly detected in the absence of overexpressed EphA2 (Fig. 6, 
C–E, first lanes). This reason is unknown, but HA-ELMO2 was 
also pulled down by control Fc alone (Fig. S2).
To investigate the role of Dock4 and ELMO2 in migration 
and invasion of MDA-MB-231 cells, we constructed two shRNAs 
targeting different sequences of human Dock4 (shDock4-1   
and -2) and an shRNA targeting human ELMO2 (shELMO2), 
which effectively reduced the endogenous protein levels in 
stimulation (Fig. 5 C). However, knockdown of Ephexin4 by 
shEphexin4-1 reduced migration of MCF7 cells and completely 
suppressed the EphA2-induced promotion of cell migration   
(Fig. 5, D and E). Similar results were obtained in cervical carci-
noma HeLa cells, which also endogenously express EphA2 and 
Ephexin4 (Fig. S1). In contrast, migration of MCF7 cells was 
also promoted by expression of RhoG-V12, and it was not   
affected by knockdown of Ephexin4 (Fig. 5 F). These results 
support the conclusion that Ephexin4 is required for the ligand- 
independent promotion of cell migration by EphA2 through 
RhoG activation.
RhoG  activates  Rac1  and  promotes  cell  migration 
through its effector ELMO and the ELMO-binding protein 
Dock4 (Hiramoto et al., 2006). In a coimmunoprecipitation ex-
periment with anti-EphA2 antibody, we found that EphA2 formed 
a complex with ELMO2 and Dock4 in MDA-MB-231 cells   
(Fig. 6 A). To confirm the interaction of EphA2 with ELMO2 and 
Dock4, Myc-EphA2 was coexpressed with HA-ELMO2, Flag-
Dock4, or both in HEK293T cells, and the cell lysates were   
immunoprecipitated with anti-Flag antibody. The interaction   
between Myc-EphA2 and Flag-Dock4 without HA-ELMO2   
expression was very weak, but it was clearly detected in the pres-
ence of HA-ELMO2 (Fig. 6 B). The interaction between EphA2 
and ELMO2–Dock4 was also observed by immunoprecipita-
tion  with  ephrinA1-Fc  in  HEK293T  cells  cotransfected  with   
HA-ELMO2, Flag-Dock4, and Myc-EphA2 (Fig. 6 C). Collec-
tively, our results suggest that EphA2 forms a ternary complex 
with ELMO2 and Dock4. The weak interaction between EphA2   
and Dock4 without ELMO2 expression may be caused by an   
Figure 4.  EphA2 and Ephexin4 mediate EGF-induced RhoG activation in MDA-MB-231 cells. (A) MDA-MB-231 cells were stimulated with EGF for the 
indicated times, and RhoG activity was analyzed by the GST-ELMO pull-down assay. (B and C) MDA-MB-231 cells transfected with the indicated plasmids 
were stimulated with or without EGF for 1 min, and RhoG activity was analyzed by the GST-ELMO pull-down assay. Data are presented as the means ± 
SEM from four or five independent experiments (*, P < 0.05; t test).JCB • VOLUME 190 • NUMBER 3 • 2010   468
Dock family members localize mainly in the cytoplasm, 
and the translocation to the plasma membrane is essential for 
their signaling and functions (Côté et al., 2005). We previously 
showed that interaction of active RhoG with ELMO2 recruits the 
ELMO2–Dock4 complex to the plasma membrane (Hiramoto   
et al., 2006). Therefore, to examine whether ELMO2 and Dock4 
function downstream of the EphA2–Ephexin4–RhoG signaling 
pathway, we prepared membrane and cytosol fractions from cel-
lular homogenates of MDA-MB-231 cells expressing shRNA 
for the control Luciferase, EphA2, RhoG, or Ephexin4 in the ab-
sence and presence of chemotactic stimulus EGF and analyzed 
the distributions of ELMO2 and Dock4 by immunoblotting with 
anti-Dock4 and anti-ELMO2 antibodies. In the control cells, 
EGF stimulation enhanced the levels of ELMO2 and Dock4 in 
the membrane fractions. However, knockdown of EphA2, RhoG, 
or Ephexin4 suppressed the EGF-induced membrane recruit-
ment of ELMO2 and Dock4 (Fig. 8 A). The efficiency of cell 
fractionation was shown by immunoblotting with anti-GAPDH 
(glyceraldehyde-3-phosphate  dehydrogenase;  cytosol  protein) 
and anti-EphA2 (membrane protein) antibodies, and EGF stimu-
lation had no effect on their distributions (Fig. 8 A). Collectively, 
our results suggest that EphA2- and Ephexin4-mediated RhoG 
activation recruits the ELMO2–Dock4 complex to the plasma 
membrane in response to EGF stimulation in MDA-MB-231 cells. 
MDA-MB-231 cells (Fig. 7 A). Expression of shDock4-1 or 
shDock4-2 significantly suppressed the migration and invasion of 
MDA-MB-231  cells  toward  EGF-containing  medium  (Fig.  7,   
B and C). Knockdown of ELMO2 also suppressed the EGF- 
induced migration and invasion in MDA-MB-231 cells (Fig. 7,   
D and E). Thus, Dock4 and ELMO2 are involved in the EGF- 
induced migration and invasion of MDA-MB-231 cells. We next 
performed  rescue  experiments  by  cotransfection  with  mouse 
Dock4 WT (mDock4-WT), which was resistant to the human 
Dock4  shRNA  shDock4-2.  Expression  of  mDock4-WT  com-
pletely rescued the impaired cell migration caused by shDock4-2. 
However, cotransfection with a mutant of mouse Dock4 (mDock4-
AAA), which contains mutations in the Rac GEF domain and has 
no ability to activate Rac (Hiramoto et al., 2006), had no effect 
(Fig. 7 F). These results suggest that Dock4 mediates the migra-
tion and invasion of MDA-MB-231 cells through the activation of 
Rac. However, expression of RhoG-V12, which could rescue the 
cell migration defect caused by knockdown of EphA2 or Ephexin4 
(Fig. 3, D and G), did not rescue in Dock4 knockdown cells   
(Fig. 7 G), supporting a model in which RhoG acts upstream of 
Dock4. Although Dock180 is another member of Dock family 
GEFs that activates Rac, expression of Flag-Dock180 had little 
effect on migration of Dock4 knockdown cells (Fig. 7 G), sug-
gesting that this function is specific to Dock4.
Figure 5.  Ectopic expression of EphA2 in MCF7 cells promotes cell migration through Ephexin4. (A) Expression of EphA2 in MCF7 and MDA-MB-231 
breast cancer cell lines was analyzed by immunoblotting with anti-EphA2 and anti–-tubulin antibodies. (B) Cell lysates from MCF7 cells were immuno-
precipitated with control or anti-EphA2 antibody, and bound proteins and total cell lysates were analyzed by immunoblotting with anti-EphA2 and anti-
Ephexin4 antibodies. IP, immunoprecipitation. (C) Transwell migration assays using MCF7 cells transfected with GFP alone or together with Myc-EphA2 for 
6 h. Data are presented as the means ± SEM from four independent experiments (**, P < 0.01; t test). (D) Cell lysates from MCF7 cells transfected with 
control or Ephexin4-1 shRNA were analyzed by immunoblotting with anti-Ephexin4 and anti–-tubulin antibodies. (E and F) Transwell migration assays 
using MCF7 cells transfected with YFP and the indicated plasmids for 24 h. Data are presented as the means ± SEM from three or four independent experi-
ments (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant; t test).469 Role of Ephexin4 in EphA2 signaling • Hiramoto-Yamaki et al.
EphA2 shRNA in the absence and presence of EGF by pull-
down assays with GST-fused CRIB domain of Pak. In the 
control  cells,  stimulation  with  EGF  induced  a  rapid  in-
crease in the amount of active Rac1. However, knockdown of   
EphA2 significantly suppressed the Rac1 activation by EGF 
(Fig. 8 B). Thus, EphA2 mediates Rac activation in response 
to EGF stimulation.
To further confirm that Rac activation occurs downstream 
of EphA2, HeLa cells were transfected with Myc-tagged EphA2, 
There is Dock4 but not ELMO2 in the membrane fraction   
under RhoG knockdown conditions. It is possible that Dock4 
is involved in other cellular functions independent of RhoG 
activation, for example the regulation of cell–cell adhesion 
and receptor endocytosis (Yajnik et al., 2003; Upadhyay et al., 
2008; Kawada et al., 2009). Next, to examine whether  Rac   
was indeed activated upon EGF stimulation and that knock-
down of EphA2 prevented it, we measured Rac activity in 
MDA-MB-231  cells  expressing  the  control  Luciferase  or 
Figure 6.  ELMO2 and Dock4 form a complex with EphA2. (A) Cell lysates from MDA-MB-231 cells were immunoprecipitated with control or anti-EphA2 
antibody, and bound proteins and total cell lysates were analyzed by immunoblotting with antibodies against EphA2, ELMO2, and Dock4. (B) Cell lysates 
from HEK293T cells transfected with Flag-tagged Dock4, HA-tagged ELMO2, and Myc-tagged EphA2 were immunoprecipitated with anti-Flag antibody, 
and bound proteins and total cell lysates were analyzed by immunoblotting with antibodies against Flag, HA, and Myc. (C–E) Cell lysates from HEK293T 
cells transfected with the indicated plasmids were immunoprecipitated with ephrinA1-Fc, and bound proteins and total cell lysates were analyzed by immuno-
blotting. (F) Cell lysates from MDA-MB-231 cells transfected with control or RhoG shRNA were immunoprecipitated with control or anti-EphA2 antibody, 
and bound proteins and total cell lysates were analyzed by immunoblotting with antibodies against EphA2, ELMO2, and Dock4. (G) Cell lysates from 
HEK293T cells transfected with the indicated plasmids were immunoprecipitated with anti-Flag antibody, and bound proteins and total cell lysates were 
analyzed by immunoblotting. IP, immunoprecipitation.JCB • VOLUME 190 • NUMBER 3 • 2010   470
In Fig. 1 D, expression of Flag-tagged Ephexin4 induced 
no obvious increase in the Rac1 activity in HEK293T cells. A pos-
sible reason for this might be because of the low level of RhoG ex-
pression in HEK293T cells (unpublished data). Therefore, we 
examined whether Rac1 was activated after overexpression   
and the Rac activity was measured. Expression of EphA2 
significantly increased Rac1 activity, which was suppressed 
by knockdown of Ephexin4 or RhoG (Fig. 8, C and D). These 
results suggest that EphA2 activates Rac1 through Ephexin4 
and RhoG.
Figure 7.  Dock4-mediated activation of Rac is required for the cell migration and invasion in MDA-MB-231 cells. (A) Cell lysates from MDA-MB-231   
cells transfected with control, Dock4, or ELMO2 shRNA were analyzed by immunoblotting with anti-Dock4, anti-ELMO2, and anti–-tubulin antibodies.   
(B and D) Transwell migration assays using MDA-MB-231 cells transfected with YFP alone or together with the indicated shRNAs in the presence of EGF   
for 4 h. Data are presented as the means ± SEM from three or four independent experiments (*, P < 0.05; **, P < 0.01; t test). (C and E) Matrigel invasion 
assays using MDA-MB-231 cells transfected with YFP alone or together with the indicated shRNAs in the presence of EGF for 24 h. Data are presented   
as the means ± SEM from three independent experiments (**, P < 0.01; ***, P < 0.001; t test). (F and G) Transwell migration assays using MDA-MB-231 
cells transfected with YFP and the indicated plasmids in the presence of EGF for 6 h. Data are presented as the means ± SEM from three or four indepen-
dent experiments (*, P < 0.05; **, P < 0.01; ***, P < 0.001; ns, not significant; t test).471 Role of Ephexin4 in EphA2 signaling • Hiramoto-Yamaki et al.
Figure 8.  EphA2 and Ephexin4 mediate the membrane recruitment of the ELMO2–Dock4 complex and activation of Rac1. (A) The control (shControl), 
EphA2 (shEphA2), Ephexin4 (shEphexin4), or RhoG (shRhoG) knockdown MDA-MB-231 cells were stimulated with or without EGF for 1 min, and the 
cellular homogenates separated into the cytosol (C) and the membrane (M) fractions were analyzed by immunoblotting with anti-ELMO2 and anti-Dock4 
antibodies. The membrane/cytosol ratio of Dock4 was analyzed by ImageJ software. Data are presented as the means ± SEM from three independent 
experiments (*, P < 0.05; t test). Immunoblotting with anti-GAPDH (cytosol protein) and anti-EphA2 (membrane protein) antibodies shows efficiency of cell 
fractionation (right). (B) MDA-MB-231 cells transfected with the indicated plasmids were stimulated with or without EGF for 1 min, and Rac1 activity was 
analyzed by the GST-CRIB pull-down assay. Data are presented as the means ± SEM from five independent experiments (*, P < 0.05; t test). (C–E) HeLa 
cells were transfected with the indicated plasmids, and Rac1 activity was analyzed by the GST-CRIB pull-down assay. Data are presented as the means ± 
SEM from five (C), four (D), or three (E) independent experiments (*, P < 0.05; **, P < 0.01; ***, P < 0.001; t test).JCB • VOLUME 190 • NUMBER 3 • 2010   472
is well known as a critical component of actin-rich protrusions   
in migrating and invading cancer cells and has a crucial role in 
promoting cell motility and invasion (Weaver, 2008). EphA2 
was colocalized with cortactin at the tip of protrusion in migrat-
ing MDA-MB-231 cells through the pore of the Transwell filter 
(Fig. 9 A). Immunofluorescence staining with anti-Dock4 anti-
body revealed that Dock4 was colocalized with EphA2 and cor-
tactin at the tip of cell protrusion into the pore (Fig. 9, B and C). 
We could not obtain clear images of the localization of Ephexin4, 
of Ephexin4 in HeLa cells, which express a high amount of en-
dogenous RhoG. In HeLa cells, expression of Flag-Ephexin4 
significantly increased Rac1 activity, which was suppressed by 
knockdown of RhoG (Fig. 8 E). These results support a model in 
which Rac1 is activated downstream of Ephexin4 and RhoG.
To determine whether EphA2 cooperates with Dock4 in 
migrating cells, we investigated the subcellular localization of 
EphA2  and  Dock4  in  MDA-MB-231  cells  migrating  toward 
EGF-containing medium through the Transwell filters. Cortactin 
Figure 9.  EphA2, Dock4, and RhoG are colocalized with cortactin at the tip of protrusion in migrating MDA-MB-231 cells. (A–E) MDA-MB-231 cells were 
seeded on the Transwell filters in the presence of 10 ng/ml EGF under the filter and incubated for 2 h. Then cells were subjected to immunofluorescent 
staining. Images of the z-plane are shown in white boxes, and selected positions of z-plane images are indicated with white lines. About 80 cells were 
examined under each condition. (F–I) Control (F and G) or EphA2 knockdown (H and I) MDA-MB-231 cells were seeded on coverslips and subjected to 
immunofluorescent staining. Bars: (A–E) 10 µm; (F–I) 20 µm.473 Role of Ephexin4 in EphA2 signaling • Hiramoto-Yamaki et al.
(Shamah et al., 2001; Sahin et al., 2005; Fu et al., 2007). 
Ephexin1 interacts with the kinase domain of EphA4 through 
the DH-PH motif of Ephexin1 (Shamah et al., 2001). The inter-
action between Ephexin4 and EphA2 also requires the DH do-
main of Ephexin4 and the kinase domain of EphA2, suggesting 
that  Ephexin1  and  Ephexin4  interact  with  EphA  receptors 
through a similar manner, although it is unknown whether there 
are binding specificities between Ephexin subfamily GEFs and 
EphA receptors. Our results also demonstrate that the inter-
action between Ephexin4 and EphA2 is enhanced by the deletion 
of the SAM domain of EphA2, suggesting that the SAM do-
main negatively regulates their interaction. In a recent study, 
several growth factors, including EGF, stimulate phosphoryla-
tion of EphA2 at a residue of serine 897 through Akt, and this 
phosphorylation is required for the EphA2-mediated ligand- 
independent promotion of cell migration and invasion (Miao   
et al., 2009). Because serine 897 of EphA2 is located in a linker 
probably because our Ephexin4 antibody was not suitable for 
immunofluorescence staining of endogenous Ephexin4 (unpub-
lished data). Instead, RhoG was also colocalized with EphA2 
and cortactin (Fig. 9, D and E). Because knockdown of EphA2 
suppresses the formation of protrusions and migration of the 
cells, we examined the effect of EphA2 knockdown on colocal-
ization of Dock4 and RhoG with cortactin in MDA-MB-231 
cells on glass coverslips. In the control cells expressing Lucifer-
ase shRNA, Dock4 and RhoG were colocalized with cortactin at 
the cell periphery (Fig. 9, F and G). In contrast, diffuse Dock4 
and RhoG staining was observed in EphA2 knockdown cells, 
and they were not colocalized with cortactin (Fig. 9, H and I). 
The specificity of Dock4 or RhoG staining with anti-Dock4 or 
anti-RhoG antibody was verified with Dock4 or RhoG knock-
down MDA-MB-231 cells (Fig. S3). Thus, these findings sug-
gest that EphA2 cooperates with RhoG and Dock4 at the tips of 
cortactin-rich protrusions to promote cell migration.
Discussion
EphA2 is a member of Eph family receptor tyrosine kinases that 
is strongly expressed in highly invasive breast cancers (Merlos-
Suárez and Batlle, 2008; Pasquale, 2008). EphA2 acts as a down-
stream effector of EGF receptors to promote cancer cell motility 
and  invasion,  independently  of  the  ligand  ephrin  stimulation   
(Zelinski et al., 2001; Macrae et al., 2005; Larsen et al., 2007; 
Brantley-Sieders et al., 2008; Miao et al., 2009). In this study, we 
show that Ephexin4 is a novel binding partner for EphA2 that 
mediates ligand-independent promotion of cell migration and in-
vasion in breast cancer cells overexpressing EphA2. EphA2 and 
Ephexin4 mediate the activation of RhoG in response to EGF 
stimulation, and activated RhoG binds to ELMO2 and recruits 
ELMO2 and its binding partner Dock4 from the cytoplasm to the 
plasma membrane to promote the formation of a complex with 
EphA2 and induce Dock4-mediated activation of Rac. We also 
found that EphA2 and Dock4 are colocalized with cortactin at 
the tips of protrusions in migrating breast cancer cells. Cortactin 
is overexpressed in cancer cells and promotes cancer cell motil-
ity and invasion by the formation of actin-rich protrusions asso-
ciated with degradation of the extracellular matrix (Rothschild   
et al., 2006; Weaver, 2008; DesMarais et al., 2009). In contrast, Rac 
plays a key role in the cancer cell movement and the formation 
of protrusions in invading cancer cells (Kurisu et al., 2005; Sanz-
Moreno et al., 2008; Vega and Ridley, 2008; Yamazaki et al., 
2009), and the intracellular localization of cortactin is regulated 
by the activation of Rac1 (Weed et al., 1998). Collectively, these 
findings support a model in which recruitment of the ELMO2–
Dock4 complex to EphA2 receptor through Ephexin4-mediated 
RhoG activation triggers a local activation of Rac by Dock4, 
which can cause the formation of cortactin-rich protrusions, 
leading to the promotion of cell polarization and migration   
(Fig. 10). Our findings also suggest that EphA2 functions as a 
scaffold downstream of EGF receptor to promote the formation 
of a signaling complex that enhances the cell motility and inva-
siveness of breast cancer cells.
Ephexin1 interacts with EphA4 and regulates EphA4- 
mediated  axon  guidance  and  dendritic  spine  morphogenesis 
Figure 10.  The schematic model of EphA2-mediated promotion of cell 
migration in response to EGF stimulation in breast cancer cells. EphA2 
binds to Ephexin4 and induces the activation of RhoG in response to EGF 
stimulation. Activated RhoG recruits ELMO2 and Dock4 to form a complex 
with EphA2, leading to Rac activation and promotion of cell migration.JCB • VOLUME 190 • NUMBER 3 • 2010   474
Murga et al., 2002; Yamaki et al., 2007; Fujimoto et al., 2009). 
Therefore, the EphA2-mediated RhoG activation may also con-
tribute  to  other  malignant  cellular  behaviors  in  cancer  cells 
overexpressing EphA2.
Materials and methods
Plasmids and antibodies
The expression plasmid encoding Flag-Dock180 (pCXN2) was a gift from 
M. Matsuda (Kyoto University, Sakyo-ku, Kyoto, Japan). pCAG vector en-
coding EYFP was a gift from J. Miyazaki (Osaka University, Suita, Osaka, 
Japan)  and  T.  Saito  (Chiba  University,  Inage-ku,  Chiba,  Japan).  Human 
Ephexin4 and EphA2 were obtained from HeLa cells, and mouse Ephexin1 
was obtained from mouse brain by RT-PCR, and they were sequenced com-
pletely. WT Ephexin4 was subcloned into pCXN2-Flag or pCAG-EYFP-CAG 
vector (Saito and Nakatsuji, 2001), and Ephexin4-DH (aa 1–275 and 
481–709) and Ephexin1 were subcloned into pCXN2-Flag vector. The DH 
domain (aa 275–480) and DH-PH domain (aa 276–633) of Ephexin4 were 
subcloned into pGEX-4T-2 (GE Healthcare). WT EphA2, EphA2-KD   
(aa 1–606 and 906–976), and EphA2-SAM (aa 1–886) were sub-
cloned into pcDNA3.1 (+) vector containing Ig  leader sequences–Myc 
(Iwasato et al., 2007; Takeuchi et al., 2009). The kinase domain of EphA2 
(aa 603–823) was subcloned into pCXN2-Flag vector. Plasmids encod-
ing  Myc-tagged  human  RhoG-WT,  RhoG-V12  (G12V),  RhoG-V12A37 
(G12V and F37A), Flag-tagged mouse Dock4-WT, Dock4-AAA (M1475A, 
S1476A, and P1477A), and mouse Zizimin1 were generated as described 
previously (Katoh and Negishi, 2003; Hiramoto et al., 2006; Katoh et al., 
2006; Kuramoto et al., 2009). Plasmids encoding GST-fused human RhoG, 
Rac1, Cdc42, and RhoA were generated as described previously (Katoh et al., 
2002; Katoh and Negishi, 2003). Ephexin4 shRNAs were designed to tar-
get 19 or 21 nt of the human Ephexin4 transcript (shEphexin4-1, 5-GGAG-
GCACCAATAGCGATTAT-3;  and  shEphexin4-2,  5-GCGGAGAGCTG-
TTCTTAGT-3). Dock4, ELMO2, and EphA2 shRNAs were designed to target 
19 nt of the human Dock4 transcript (shDock4-1, 5-GCATATACCCT-
CCTCTTAT-3; and shDock4-2, 5-CCGCAAGGTCTCTCAGTTA-3), the human   
ELMO2 transcript (shELMO2, 5-TTCATCGCACCTAATAAAT-3), and the 
human EphA2 transcript (shEphA2-1, 5-GCAAGGTGCACGAATTCCA-3; 
and shEphA2-2, 5-CAGCCTTCGGACAGACATA-3), respectively. All of 
the targets of each transcript were designed with no significant homology to 
any mammalian gene sequence and were expressed by using an shRNA ex-
pression vector pSilencer-hygro (Applied Biosystems) or pCAG-EYFP-hU6 as 
described previously (Katoh et al., 2006; Iwasato et al., 2007; Fujimoto 
et al., 2009). RhoG shRNA or control shRNA was designed to target 19 nt 
of the human RhoG or Luciferase, respectively, as described previously 
(Katoh et al., 2006; Yamaki et al., 2007).
A rabbit pAb for Ephexin4 was raised against bacterially expressed 
GST-fused peptide, corresponding to residues 690–708 of human Ephexin4, 
and the specific antibody was purified with the peptide-conjugated affinity 
column. The antibody against Ephexin4 was used to detect endogenous 
Ephexin4 by immunoblotting at a concentration of 1 µg/ml. The antibody 
for Dock4 was used as described previously (Ueda et al., 2008). The other 
antibodies  were  purchased  commercially:  mouse  mAbs  against  Myc 
(9E10),  RhoA  (26C4),  and  Dock4  (R6Y),  rabbit  pAbs  against  EphA2   
(C-20), cortactin (H-191) and HA (Y-11), and a rat mAb against RhoG 
(1F3 B3 E5; Santa Cruz Biotechnology, Inc.); mouse mAbs against Flag 
(M2)  and  -tubulin  (Sigma-Aldrich);  a  mouse  mAb  against  Rac1  (BD); 
mouse mAbs against EphA2 (D7) and cortactin (4F11; Millipore); a rat 
mAb against HA (3F10; Roche); a rabbit pAb against Myc (MBL); a goat 
pAb  against  ELMO2  (Abcam);  control  mouse  IgG  (Jackson  Immuno-
Research Laboratories, Inc.); secondary antibodies conjugated to horse-
radish peroxidase (Dako); and secondary antibodies conjugated to Alexa 
Fluor 488 or 594 (Invitrogen). F-actin was visualized with Alexa Fluor 
488–conjugated phalloidin (Invitrogen).
Cell culture and transfection
MDA-MB-231 cells were purchased from American Type Culture Collec-
tion. MCF7 cells were gift from S. Yonehara (Kyoto University). HeLa, 
HEK293T, and MCF7 cells were grown in DME supplemented with 4 mM 
glutamine, 100 U/ml penicillin, 0.2 mg/ml streptomycin, and 10% FBS, 
and MDA-MB-231 cells were grown in DME with high glucose (Invitro-
gen) containing 10% FBS and 5% NuSerum (BD). Cells were cultured   
under humidified air containing 5% CO2 at 37°C. Cells were transfected 
with the indicated plasmids using Lipofectamine Plus (Invitrogen; for 
region between the kinase and SAM domains, phosphorylation 
of EphA2 at serine 897 by EGF-induced Akt activation may 
trigger a conformational change within the cytoplasmic region 
of EphA2 to promote the interaction with Ephexin4 and the 
Ephexin4-dependent RhoG activation. However, the tyrosine 
phosphorylation of Ephexin1 or Ephexin5/Vsm–Rho GEF by 
EphA4 enhances the GEF activity toward RhoA in response to 
ephrinA1 stimulation (Ogita et al., 2003; Sahin et al., 2005). 
Thus, although Ephexin family members bind to EphA recep-
tors through a similar region, they appear to differ in the regula-
tion of the GEF activity. In contrast to the ligand-independent 
signaling by EphA2, stimulation of EphA2 with its ligand   
ephrinA1 in cancer cells induces EphA2 receptor internalization 
and degradation, which is also mediated through the activation 
of Rac (Walker-Daniels et al., 2002; Zhuang et al., 2007). The 
Vav family of Rac-specific GEFs plays an important role in the 
regulation of ephrin-Eph endocytosis, and ephrinA1 stimulation 
causes tyrosine phosphorylation of EphA2 in the juxtamem-
brane domain and recruits Vav family GEFs to the phosphory-
lated EphA2 receptor (Cowan et al., 2005; Hunter et al., 2006). 
Thus, it is possible that EphA2 couples different GEFs in   
ligand-dependent and -independent signaling pathways.
Dock4 belongs to the Dock family of GEFs for Rho fam-
ily small GTPases and positively regulates cell migration by 
specifically activating Rac (Côté and Vuori, 2002; Hiramoto et al., 
2006; Upadhyay et al., 2008; Kawada et al., 2009). We show 
that Dock4 is expressed in breast cancer cells and is required for 
EGF-stimulated cell migration and invasion. Dock family mem-
bers, including Dock4, localize mainly in the cytoplasm, and 
the translocation to the plasma membrane is critical for the acti-
vation of Rho family GTPases in cells and their cellular func-
tions (Côté et al., 2005; Hiramoto et al., 2006; Meller et al., 
2008; Kuramoto et al., 2009). We previously reported that RhoG 
regulates Dock4 through the interaction with ELMO2 and re-
cruitment of the ELMO2–Dock4 complex from the cytoplasm 
to the plasma membrane (Hiramoto et al., 2006). In this study, 
knockdown of EphA2 or Ephexin4 in MDA-MB-231 breast 
cancer  cells  suppresses  the  activation  of  RhoG  and  RhoG- 
dependent translocation of ELMO2 and Dock4 to the plasma 
membrane induced by EGF stimulation. Thus, EphA2 and 
Ephexin4 are key upstream regulators for the RhoG–ELMO2–
Dock4 signaling pathway to control cell migration and invasion 
in MDA-MB-231 breast cancer cells. Phylogenetic analysis in-
dicates that Dock3 and Dock4 belong to the same subfamily 
within the Dock family members (Côté and Vuori, 2002). Dock3 
is expressed in melanoma cells and also positively regulates cell 
migration and invasion through activation of Rac (Sanz-Moreno 
et al., 2008). The Dock3-mediated regulation of cell movement 
in melanoma cells requires NEDD9, a member of the p130Cas, 
and a Rac downstream effector WAVE2 (Sanz-Moreno et al., 
2008). Thus, it will be interesting in future studies to investigate 
whether NEDD9 and WAVE family proteins are involved in the 
Dock4-mediated signaling in breast cancer cells.
Our results show that activation of RhoG contributes   
to  increased  migration  and  invasion  of  breast  cancer  cells.   
In addition to its role in cell migration, RhoG plays an impor-
tant role in cell proliferation and survival (Roux et al., 1997; 475 Role of Ephexin4 in EphA2 signaling • Hiramoto-Yamaki et al.
In vitro guanine nucleotide exchange assay
Fluorescence spectroscopic analysis of mant-GTP incorporation into GST-
RhoG or -Rac1 was performed using a microplate reader (GENios; Tecan) 
at 20°C. 2 µM GST-RhoG or -Rac1 was prepared and allowed to equili-
brate in exchange buffer (20 mM Tris-HCl, pH 7.5, 50 mM NaCl, 10 mM 
MgCl2, 50 mg/ml BSA, and 0.8 µM mant-GTP). After equilibration, nor-
malized amounts (400 nM) of purified GST or GST-fused DH-PH domain of 
Ephexin4 were added to the assay mixtures, and the change of mant-GTP 
fluorescence (excitation = 360 nm; emission = 440 nm) was monitored. 
Experiments were performed in triplicate for each reaction.
Transwell cell migration assay
MDA-MB-231 or MCF7 cells were transfected with GFP or YFP alone or to-
gether with the indicated plasmids and incubated for 24–72 h. The cells 
were detached with PBS containing EDTA and then resuspended in serum-
free DME. The cells were replated at a density of 1–3 × 10
4 cells onto the 
upper chamber of a Transwell filter (Costar; 8-µm pore size). The cultured 
medium (for MCF7 cells) or the medium supplemented with 10 ng/ml EGF 
(Sigma-Aldrich; for MDA-MB-231 cells) was added to the lower chamber. 
At 4–6 (for MDA-MB-231 cells) or 6–24 h (for MCF7 cells) after plating, 
cells were fixed with 4% PFA in PBS. Nonmigrated cells on the upper side 
of the filter were removed with a cotton swab. In parallel, cells were sepa-
rately plated to culture wells without the Transwell filters for estimating the 
total number of attached cells. Relative cell migration was determined by 
the number of the GFP- or YFP-positive migrated cells normalized to the total 
number of the GFP- or YFP-positive cells adhering to the plate. For each ex-
periment, the number of cells in 20 random fields on the underside of the fil-
ter was counted, and three or four independent filters were analyzed.
Matrigel cell invasion assay
MDA-MB-231 cells were transfected with YFP alone or together with the in-
dicated plasmids and incubated for 24–72 h. The cells were detached with 
PBS containing EDTA and then resuspended in serum-free DME. The cells 
were then replated at a density of 3 × 10
4 cells onto the upper chamber of 
a Matrigel invasion filter (BD; 8-µm pore size). The medium supplemented 
with 10 ng/ml EGF was added to the lower chamber. At 24 h after plating, 
cells were fixed with 4% PFA in PBS. Nonmigrated cells on the upper side 
of the filter were removed with a cotton swab. In parallel, cells were also 
separately plated to culture wells without the Matrigel filters for estimating 
the total number of attached cells. Relative cell invasion was determined by 
the number of the YFP-positive invaded cells normalized to the total number 
of the YFP-positive cells adhering to the plate. For each experiment, the 
number of cells in 20 random fields on the underside of the filter was 
counted, and three independent filters were analyzed.
Immunofluorescence microscopy
Cells  on  coverslips  were  fixed  with  4%  paraformaldehyde  in  PBS  for   
15 min and washed with PBS five times. Cells were permeabilized with 0.2% 
Triton X-100 in PBS for 10 min and incubated with 10% FBS in PBS for   
30 min to block nonspecific antibody binding. Then cells were incubated with 
primary antibodies in PBS or Can Get Signal Immunostain Immunoreaction 
Enhancer SolutionA (TOYOBO) for 24 h. After wash with PBS at once, cells 
were incubated with secondary antibodies conjugated with Alexa Fluor 
488 or 594 in PBS for 1 h, washed with PBS for 30 min, and mounted in 
ProLong Gold antifade reagent (Invitrogen). For F-actin staining in HeLa 
cells, cells were incubated with Alexa Flour 594–conjugated phalloidin in 
PBS for 1 h, washed with PBS for 30 min, and mounted in 90% glycerol 
containing  0.1%  p-phenylenediamine  dihydrochloride  in  PBS.  Images 
were captured at RT using IM50 software (Leica) and a microscope (Eclipse 
E800; Nikon) with a 40× NA 0.75 objective (Nikon) and a digital camera 
(DC350F; Leica).
For immunofluorescence staining of migrating cells, MDA-MB-231 
cells were replated at a density of 3 × 10
3 cells onto the upper chamber 
of the Transwell filter. The medium supplemented with 10 ng/ml EGF was 
added to the lower chamber. At 2 h after plating, cells were fixed with 4% 
PFA in PBS for 20 min and washed with PBS. The membrane of Transwell 
filter was cut off with a scalpel and kept floated in the following methods. 
Cells were permeabilized with 0.2% Triton X-100 in PBS for 10 min and 
incubated with 10% FBS in PBS for 30 min to block nonspecific antibody 
binding. Then cells were incubated with primary antibodies in PBS or Can 
Get Signal Immunostain Immunoreaction Enhancer SolutionA for 24 h.   
After wash with PBS at once, cells were incubated with secondary anti-
bodies conjugated with Alexa Fluor 488 or 594 in PBS for 1 h, washed 
with PBS for 30 min, and mounted in ProLong Gold antifade reagent. To 
obtain a z-plane image, optical sections of images were captured through 
the cell in 0.50-µm steps at RT using a C1 laser-scanning confocal imaging 
HEK293T cells) or Lipofectamine 2000 (for HeLa, MCF7, and MDA-MB-231 
cells),  according  to  the  manufacturer’s  instructions.  In  some  experi-
ments, MDA-MB-231 and HeLa cells transfected with the shRNA expres-
sion vector were used after selection with 200 µg/ml and 300 µg/ml   
hygromycin-B, respectively.
Pull-down assay, immunoprecipitation, and immunoblotting
In vitro binding assays were performed using lysates of HEK293T cells 
transfected with Flag-tagged Ephexin4 and nucleotide-free forms of recom-
binant GST-fused Rho GTPases prepared from Escherichia coli. To prepare 
nucleotide-free  GTPases,  purified  proteins  were  incubated  in  buffer  C   
(20 mM Tris-HCl, pH 7.5, 50 mM NaCl, 0.1% Triton X-100, 5% glycerol, 
1 mM PMSF, and 1 mM DTT) containing 5 mM EDTA for 20 min at 25°C 
and kept on ice for 10 min. HEK293T cells transfected with Flag-tagged 
Ephexin4 were lysed with buffer C, and the cell lysates were then centri-
fuged at 16,000 g for 10 min at 4°C. The supernatants were incubated 
with 25 µg GST or GST-fused GTPases and glutathione-Sepharose beads 
for 1 h at 4°C. After the beads were washed with ice-cold buffer C, the 
bound proteins were eluted in Laemmli sample buffer and analyzed by SDS-
PAGE and immunoblotting.
For immunoprecipitation, HEK293T cells cotransfected with the indi-
cated plasmids were lysed for 10 min with ice-cold cell lysis buffer (20 mM 
Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM MgCl2, 1% Triton X-100, 1 mM 
PMSF, 10 µg/ml aprotinin, and 10 µg/ml leupeptin). After centrifugation 
for 10 min at 16,000 g, the supernatants were incubated with anti-Flag 
(M2) antibody or recombinant mouse ephrinA1-Fc (R&D Systems) for 2 h 
and then with protein G–Sepharose (GE Healthcare) for 1 h. Then the 
beads were washed with the cell lysis buffer. For detecting endogenous 
binding proteins, MDA-MB-231 or MCF7 cells were lysed for 10 min with 
ice-cold cell lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1 mM 
MgCl2, 1% Triton X-100, 10 mM NaF, 1 mM Na3VO4, 1 mM PMSF,   
10 µg/ml aprotinin, and 10 µg/ml leupeptin). After centrifugation for   
10 min at 16,000 g, the supernatants were incubated with anti-EphA2 (D7) 
antibody for 1.5 h, followed by incubation with protein G–Sepharose for   
1 h. Then the beads were washed with the cell lysis buffer.
For immunoblot analysis, proteins were separated by SDS-PAGE 
and were electrophoretically transferred onto a polyvinylidene difluoride 
membrane (Millipore). The membrane was blocked with 3% low fat milk in 
Tris-buffered saline and then incubated with primary antibodies. The pri-
mary antibodies were detected with horseradish peroxidase–conjugated 
secondary antibodies and an ECL detection kit (GE Healthcare).
Measurement of Rho GTPase activity in cells
Measurement of RhoG, Rac1, Cdc42, or RhoA activity in cells was per-
formed according to the modified methods of Benard et al. (1999; for 
RhoG, Rac1, and Cdc42) and Ren et al. (1999; for RhoA). The CRIB do-
main  of  Pak  (aa  70–150),  the  N-terminal  RhoG-binding  domain  of 
ELMO2 (ELMO-NT; aa 1–362), and the RhoA-binding domain of Rho-
tekin (aa 2–89) were expressed in E. coli as fusion proteins with GST, pu-
rified on glutathione-Sepharose beads, and isolated from the beads with 
16 mM reduced glutathione. The purified proteins were dialyzed with   
10 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM MgCl2, and 0.1 mM DTT 
and stored at 80°C. Protein concentration was determined by compar-
ing with BSA standards after SDS-PAGE and by staining with Coomassie 
brilliant blue. To determine RhoG, Rac1, or Cdc42 activity in HEK293T 
or HeLa cells, transfected cells were serum-starved and then lysed with 
the ice-cold cell lysis buffer (50 mM Tris-HCl, pH 7.5, 100 mM NaCl,   
10 mM MgCl2, 1% Triton X-100, 10% glycerol, 1 mM DTT, 1 mM PMSF, 
10 µg/ml aprotinin, and 10 µg/ml leupeptin) containing 5 µg GST-CRIB 
or 20 µg GST–ELMO-NT. To measure RhoG or Rac1 activity in MDA- 
MB-231 cells, cells were stimulated with 10 ng/ml EGF for the indicated 
times before cell lysis. Cell lysates were then centrifuged for 5 min at 
10,000 g at 4°C, and the supernatant was incubated with glutathione-
Sepharose beads for 30 min at 4°C. The beads were washed with lysis 
buffer, and bound proteins were analyzed by SDS-PAGE and immuno-
blotting. For measurement of RhoA activity in HEK293T cells, transfected 
cells were serum-starved and lysed with ice-cold cell lysis buffer (50 mM 
Tris-HCl, pH 7.5, 500 mM NaCl, 30 mM MgCl2, 1% Triton X-100, 10% 
glycerol, 1 mM DTT, 1 mM PMSF, 10 µg/ml aprotinin, and 10 µg/ml leu-
peptin) containing 20 µg of GST-fused RBD of mouse Rhotekin. The cell 
lysates were centrifuged for 5 min at 16,000 g at 4°C, and the super-
natants were incubated with glutathione-Sepharose beads for 50 min at 
4°C. The beads were washed with wash buffer (50 mM Tris-HCl, pH 7.5, 
150 mM NaCl, 30 mM MgCl2, 0.5% Triton X-100, 1 mM DTT, 1 mM 
PMSF, 10 µg/ml aprotinin, and 10 µg/ml leupeptin), and bound proteins 
were analyzed by SDS-PAGE and immunoblotting.JCB • VOLUME 190 • NUMBER 3 • 2010   476
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system (EZ-C1 version 3.20 software; Nikon) and a microscope (Eclipse 
TE2000-U; Nikon) with a 60× NA 1.40 oil objective (Nikon) and a digital 
camera (DXM1200C; Nikon). All images were prepared with Photoshop 
7.0 (Adobe).
Separation of membrane and cytosol fractions
MDA-MB-231 cells were stimulated with 10 ng/ml EGF for 1 min and then 
suspended in ice-cold buffer A (20 mM Tris-HCl, pH 7.5, 150 mM NaCl, 
50 mM NaF, 1 mM Na3VO4, and 1 mM PMSF). After rapid freezing in liq-
uid nitrogen and thawing in a water bath, cells were centrifuged at 16,000 g 
for 10 min at 4°C. The supernatant was removed and used as a cytosol 
fraction. After washing the pellet with buffer A, it was lysed with buffer A 
containing 1% Triton X-100 and centrifuged at 10,000 g for 10 min at 
4°C. The supernatant was removed and used as a membrane fraction. 
Both cytosol and membrane fractions were separated by SDS-PAGE and 
analyzed by immunoblotting.
Data analysis
Densitometry analysis was performed with ImageJ free image analysis soft-
ware (National Institutes of Health), and relative RhoG or Rac1 activity was 
determined by the amount of GTP-bound RhoG or Rac1 bound to GST-
ELMO or -CRIB normalized to the amount of total RhoG or Rac1 in cell   
lysates, respectively. Statistical significance was established by t test using 
SPSS software (version 16.0; SPSS, Inc.).
Online supplemental material
Fig.  S1  shows  that  Ephexin4  mediates  promotion  of  cell  migration  by 
EphA2 in HeLa cells in Transwell migration assays. Fig. S2 shows immuno-
precipitation  with  control  Fc  or  ephrinA1-Fc  in  HEK293T  cell  lysates   
transfected  with  HA-ELMO2  alone  or  together  with  Myc-EphA2.  Fig.  S3 
shows the specificity of Dock4 or RhoG staining with anti-Dock4 or anti-
RhoG  antibody  using  Dock4  or  RhoG  knockdown  MDA-MB-231  cells. 
Online  supplemental  material  is  available  at  http://www.jcb.org/cgi/ 
content/full/jcb.201005141/DC1.
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